FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1054-1057 March 4, 2004 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Colao, A. Related Article by Schlechte, J. A. PubMed Citation

To the Editor: In the study protocol described by Colao et al. (Nov. 20 issue),¹ cabergoline was given at a dose of 0.5 mg per week to patients with nontumoral hyperprolactinemia, microprolactinomas, or macroprolactinomas and then stopped abruptly. I propose that cabergoline be tapered off rather than abruptly stopped, to avoid potential rebound hyperprolactinemia. The dose can be reduced from the typical dose of 0.25 mg twice a week, to 0.25 mg once a week, and then to 0.25 mg every other week before discontinuation. Serum prolactin levels can be measured one month after dose reduction and the reduction continued . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.